GPR97 variants and their influence on pathological myopia: implications for glucocorticoid treatment
Research in Pharmaceutical Sciences · 2026-03 · 21 (2) · 164-177
DOI: 10.4103/rps.rps_217_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 24.04.2026. Verfasst von Qi Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose: Pathologic myopia (PM) is a severe form of myopia associated with structural changes in the eye, leading to vision impairment. Identifying genetic factors that contribute to PM can enhance the treatment of the condition. This study aimed to investigate the association between the GPR97 and PM and to evaluate the impact of glucocorticoid treatment on PM. Experimental approach: A cohort of 412 sporadic PM patients underwent Sanger sequencing and genotyping for GPR97 gene variants. Thirty-one PM patients with various GPR97 genotypes received glucocorticoid and brinzolamide treatment over 24 months. Real-time PCR was employed to examine the target gene mRNA expression. A scratch assay was performed to detect cell migration ability. Findings/Results: A significant association was identified between GPR97 rs76688596 genotypes and PM occurrence. The CC genotype was linked to elevated intraocular pressure (IOP). In human scleral fibroblasts, overexpression of GPR97 Arg396 resulted in upregulation of IOP-related genes serine/arginine-rich splicing factor 3, peptidyl-prolyl cis-trans isomerase 4, peptidyl-prolyl cis-trans isomerase 5, and nuclear receptor subfamily 3 group C member 1. The GPR97 Arg396 mutation inhibited the glucocorticoid-GPR97 axis and reduced cell migration ability. Clinically, CC genotype carriers exhibited significant improvements in axial length, spherical equivalent, IOP, best-corrected visual acuity, and visual field mean sensitivity with glucocorticoid treatment. Conclusion and implications: The study revealed that the GPR97 rs76688596 G > C variant is associated with PM pathogenesis, influencing gene expression related to IOP. The differential response to glucocorticoid treatment among GPR97 genotypes suggests personalized therapeutic potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
- Institute of Translational Medicine, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
Zitieren
APA
Zhao, Q., Mu, Z., Gu, H., Cheng, W., Xu, Y., Jiang, Y., Wu, G., & Pu, L. (2026). GPR97 variants and their influence on pathological myopia: implications for glucocorticoid treatment. Research in Pharmaceutical Sciences, 21(2), 164-177. https://doi.org/10.4103/rps.rps_217_24
Vancouver
Zhao Q, Mu Z, Gu H, Cheng W, Xu Y, Jiang Y, et al. GPR97 variants and their influence on pathological myopia: implications for glucocorticoid treatment. Research in Pharmaceutical Sciences. 2026;21(2):164-177. doi:10.4103/rps.rps_217_24
BibTeX
@article{Zhao2026,
author = {Zhao, Qi and Mu, Zhaoxia and Gu, Huihui and Cheng, Wei and Xu, Yulian and Jiang, Yingying and Wu, Geping and Pu, Lijun},
title = {GPR97 variants and their influence on pathological myopia: implications for glucocorticoid treatment},
journal = {Research in Pharmaceutical Sciences},
year = {2026},
volume = {21},
number = {2},
pages = {164--177},
doi = {10.4103/rps.rps_217_24}
}
EUVIMED